These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 11465069)

  • 21. Definition by specific antisense oligonucleotides of a role for protein kinase C alpha in expression of differentiation markers in normal and neoplastic mouse epidermal keratinocytes.
    Lee YS; Dlugosz AA; McKay R; Dean NM; Yuspa SH
    Mol Carcinog; 1997 Jan; 18(1):44-53. PubMed ID: 9022812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Ca2+-dependent PKC isoforms unmasks ERK-dependent hypertrophic growth evoked by phenylephrine in adult ventricular cardiomyocytes.
    Schreckenberg R; Taimor G; Piper HM; Schlüter KD
    Cardiovasc Res; 2004 Aug; 63(3):553-60. PubMed ID: 15276481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high throughput system for the evaluation of protein kinase C inhibitors based on Elk1 transcriptional activation in human astrocytoma cells.
    Sharif TR; Sharif M
    Int J Oncol; 1999 Feb; 14(2):327-35. PubMed ID: 9917510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein kinase C isozymes as potential targets for anticancer therapy.
    Hofmann J
    Curr Cancer Drug Targets; 2004 Mar; 4(2):125-46. PubMed ID: 15032665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein kinase C signalling in pancreatic beta-cells: cellular and molecular approaches.
    Persaud SJ
    Digestion; 1997; 58 Suppl 2():86-92. PubMed ID: 9302497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of protein kinase C signaling in activated DRA transcription.
    Setterblad N; Onyango I; Pihlgren U; Rask L; Andersson G
    J Immunol; 1998 Nov; 161(9):4819-24. PubMed ID: 9794414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective protein kinase C inhibitors and their applications.
    Shen GX
    Curr Drug Targets Cardiovasc Haematol Disord; 2003 Dec; 3(4):301-7. PubMed ID: 14683472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D; Lahn M
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pros and cons of targeting protein kinase C (PKC) in the management of cancer patients.
    Leskow FC; Krasnapolski MA; Urtreger AJ
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1961-73. PubMed ID: 21470133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
    Courage C; Budworth J; Gescher A
    Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased protein kinase C activity in myotrophin-induced myocyte growth.
    Sil P; Kandaswamy V; Sen S
    Circ Res; 1998 Jun; 82(11):1173-88. PubMed ID: 9633917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity.
    Ohmori T; Arteaga CL
    Cell Growth Differ; 1998 Apr; 9(4):345-53. PubMed ID: 9563854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distinct mechanisms of differentiation of SH-SY5Y neuroblastoma cells by protein kinase C activators and inhibitors.
    Leli U; Cataldo A; Shea TB; Nixon RA; Hauser G
    J Neurochem; 1992 Apr; 58(4):1191-8. PubMed ID: 1548459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrin-induced protein kinase Calpha and Cepsilon translocation to focal adhesions mediates vascular smooth muscle cell spreading.
    Haller H; Lindschau C; Maasch C; Olthoff H; Kurscheid D; Luft FC
    Circ Res; 1998 Feb; 82(2):157-65. PubMed ID: 9468186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues.
    Jones T; Courage C; Hubbard A; Gescher A
    Biochem Pharmacol; 1997 May; 53(10):1413-8. PubMed ID: 9260867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential role of PKC inhibitors in the treatment of hematological malignancies.
    Mischiati C; Melloni E; Corallini F; Milani D; Bergamini C; Vaccarezza M
    Curr Pharm Des; 2008; 14(21):2075-84. PubMed ID: 18691117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phorbol ester stimulation of phosphatidylcholine synthesis in four cultured neural cell lines: correlations with expression of protein kinase C isoforms.
    Sproull SA; Morash SC; Byers DM; Palmer BStC ; Cook HW
    Neurochem Res; 1995 Dec; 20(12):1397-407. PubMed ID: 8789601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways.
    Meinhardt G; Roth J; Totok G
    Eur J Cell Biol; 2000 Nov; 79(11):824-33. PubMed ID: 11139146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.